Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aslan Pharmaceuticals Ltd ADR (ASLN)

Aslan Pharmaceuticals Ltd ADR (ASLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?

Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Sanofi (SNY) have performed compared to their sector so far this year.

ASLN : 0.5053 (+1.02%)
SNY : 46.24 (+0.67%)
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?

Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Atreca, Inc. (BCEL) have performed compared to their sector so far this year.

ASLN : 0.5053 (+1.02%)
BCEL : 0.0810 (unch)
Is Apexigen, Inc. (APGN) Stock Outpacing Its Medical Peers This Year?

Here is how Apexigen, Inc. (APGN) and ASLAN Pharmaceuticals Ltd. (ASLN) have performed compared to their sector so far this year.

APGN : 0.3851 (+8.48%)
ASLN : 0.5053 (+1.02%)
Bears are Losing Control Over ASLAN Pharmaceuticals Ltd. (ASLN), Here's Why It's a 'Buy' Now

ASLAN Pharmaceuticals Ltd. (ASLN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions...

ASLN : 0.5053 (+1.02%)
Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?

Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Aspira (AWH) have performed compared to their sector so far this year.

ASLN : 0.5053 (+1.02%)
AWH : 3.39 (-1.74%)
DBV (DBVT) Up as FDA Lifts Partial Hold on Peanut Allergy Study

The FDA lifts the partial clinical hold on DBV Technologies' (DVBT) phase III VITESSE study of a modified Viaskin Peanut patch in peanut-allergic children aged four to seven years. Stock rises.

ADAP : 1.0500 (-9.48%)
DBVT : 0.6950 (+0.07%)
ASLN : 0.5053 (+1.02%)
IMCR : 55.54 (-1.75%)
ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly

ProQR (PRQR) expands its existing licensing and collaboration agreement with Eli Lilly for the discovery, development and commercialization of new genetic medicines.

LLY : 750.77 (-0.12%)
PRQR : 2.05 (-7.05%)
ASLN : 0.5053 (+1.02%)
IMCR : 55.54 (-1.75%)
ORIC Rises on Team-Up With Pfizer for Multiple Myeloma Study

ORIC inks a collaboration deal with Pfizer for a phase II study evaluating ORIC-533 in combination with the latter's elranatamab in multiple myeloma. Stock up in after-hours trading.

PFE : 25.91 (+0.19%)
ASLN : 0.5053 (+1.02%)
ORIC : 9.54 (-2.65%)
IMCR : 55.54 (-1.75%)
Mirati's (MRTX) Krazati Gets Breakthrough Therapy Tag for CRC

The FDA bestows a Breakthrough Therapy designation to Mirati's (MRTX) Krazati (adagrasib) for treating patients with advanced, KRAS-mutated colorectal cancer.

MRK : 126.19 (+0.36%)
AMGN : 265.51 (-0.66%)
MRTX : 58.70 (-0.17%)
ASLN : 0.5053 (+1.02%)
Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis

The CHMP recommends approval of Sanofi (SNY) and partner Regeneron's Dupixent for the treatment of adults and adolescents with eosinophilic esophagitis.

REGN : 898.56 (-0.68%)
SNY : 46.24 (+0.67%)
ASLN : 0.5053 (+1.02%)
IPHA : 2.42 (-2.42%)

Barchart Exclusives

3 Gold Stocks to Buy as Israel Weighs Iran Response
With geopolitical tensions simmering after Iran's weekend missile launch on Israel, demand for gold stayed strong in Monday's session. For investors seeking safe-haven exposure to the asset, here are three gold stocks that analysts recommend. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar